ISHRS MSCI China S-Cap

Yashen Pharmaceuticals' Olverabatinib Granted FDA and EMA Phase III Clinical Trial Approval

Everbright Environment Receives CSROA's Registration Acceptance Notice for Proposed Asset-Backed Notes Issuance

JPMorgan Cuts Stake in Mingsheng Group

Bank of America Raises Target Price for Mingshi Group to 50 Yuan and Reiterates 'Buy' Rating

JPMorgan Increases Stake in Mingshi Group to 6%

Zongan Insurance Launches Dad and Mom Safe and Healthy Bone Fracture Insurance

ZA Bank and Zhongan International Donate $5 Million to Support Emergency Relief in Tai Po

JPMorgan Reduces Holdings in Mingshi Group

心动公司与 Golden Arc 签订战略合作及融资协议

Zai Lab's Chief Legal Officer Sells Company Common Stock

Handlink Corporation Anticipates Continuous Revenue Growth in Gaming Business from 2025 to 2027

Guokin Securities First Coverage of Xing 动 with “Buy” Rating

CICC and CLSA analysts maintain buy rating for 金山云

UBS and BofA Securities Maintain Buy Rating on 金山云

Goldman Sachs Maintains Hold Rating on Kingsoft Cloud Holdings

AI Technologies Drive Significant Business Growth for Tech Giants

Kingsoft Cloud Reports 31% Q3 Revenue Growth, Upgrades Cloud and AI Computing Platforms

Kingsoft Cloud released FY2025 Q3 earnings on November 19 Pre-Market (BJT), actual revenue HKD 2.709 B (forecast HKD 2.7 B), actual EPS HKD -0.0012 (forecast HKD -0.083)

Kingsoft Cloud released FY2025 9 Months Earnings on November 19 Pre-Market (BJT), actual revenue HKD 7.39 B, actual EPS HKD -0.2162

BofA Securities Sees Positive Outlook for China Everbright Environment's A-Share Issuance

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

AAPG

AAPGV

06855

Ascentage Pharma has received FDA and EMA clearance for a global Phase III study of olverembatinib in Ph+ ALL. This approval allows patient enrollment across multiple countries, potentially accelerating olverembatinib's registration in the US and Europe.

Reuters

Ascentage Pharma

Ascentage Pharma Group International ADR - W/I

ASCENTAGE-B

Ascentage Pharma Wins FDA and EMA Clearance for Global Phase III Study of Olverembatinib in Ph+ ALL

00425

Bank of America Securities analyst maintained a Buy rating on Minth Group, setting a price target of HK$50.00. Shares closed at HK$33.66. The consensus is a Strong Buy with an average price target of $5.85, indicating a -82.62% downside. TR | OpenAI – 4o also reiterated a Buy rating with a HK$39.00 target.

Tip Ranks

MINTH GROUP

Bank of America Securities Remains a Buy on Minth Group (MNTHF)

BTIG analyst Justin Zelin maintained a Buy rating for Ascentage Pharma Group International Unsponsored ADR, setting a price target of $50.00. Zelin, a 4-star analyst with an 8.0% average return, focuses on the Healthcare sector. The analyst consensus for Ascentage Pharma is Strong Buy, with a price target consensus of $49.67.

BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)

09688

ZLAB

Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. The company granted options for 11,800 ADSs to three employees and restricted share units for 22,665 ADSs to six employees. This move is part of their market-competitive approach to incentivize employee performance. Zai Lab is a biopharmaceutical company focusing on oncology, autoimmune disorders, and infectious diseases.

- Zai Lab Ltd announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan, providing options for 11,800 ADSs to three employees and restricted units for 22,665 ADSs to six employees.  
- This initiative aims to incentivize employee performance without performance targets or clawback mechanisms, reflecting a competitive market approach.  
- The current analyst rating for Zai Lab Ltd (HK:9688) is a Hold, with a price target of HK$14.50, and the company focuses on developing innovative therapies in oncology, autoimmune disorders, and infectious diseases.

ZAI LAB

Zai Lab

Zai Lab Limited Announces Equity Incentive Grants